#1COPYRIGHT © ABCELLERA CORPORATE OVERVIEW JP Morgan Healthcare Conference 2023 AbCellera#2CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 2 DISCLAIMER This entation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 3 AbCellera is an antibody discovery engine that delivers optimal clinical candidates to the clinic - and to patients with greater precision and speed. - HYPOTHESIS Investments in technology can improve the productivity of drug development. PHILOSOPHY Long-term value creation begins with building a great company that can create multiple products.#4CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 4 DRUG DEVELOPMENT HAS THREE STEPS. Target Identification IDEATION Drug Discovery regulations, technology, science, manufacturing, lab space, talent PRODUCT CREATION 3 to 5 years 1000+ steps Clinical Development PRODUCT TESTING 7 to 10 years#5CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 5 TECHNOLOGY CAN MAKE A BIG IMPACT ON PRODUCT CREATION. Illustrative drug development investment profile: Years since program start Stage of program development I Technology intensive 1y 2y Discovery to IND 3y 4y 5y Phase 1 6y 7y Phase 2 8y 9y Phase 3 POS: >5% 10y 11y 12y 13y 14y 15y Commercial Sales 16y Peak sales ~$1B 17y 18y 19y 20y 21y#6CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 6 STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. STRATEGY #2 NO Build a large and diversified portfolio of stakes in future antibody therapeutics.#7CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 7 STRATEGY #1 Be best in world in antibody therapeutics from target to the clinic. from TARGET TECHNOLOGY DATA SCIENCE THE ENGINE EXPERTS INFRASTRUCTURE INTEGRATION X to PATIENTS 2x faster solve the unsolvable highest quality unprecedented scale#8CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 8 SPEED $100M+ NPV by accelerating approval of an average antibody drug by 1 year NEW MARKETS $100B+ new market opportunities unlocked by drugging the undruggable Billions sales, profit, value by being first to market LEVEL THE PLAYING FIELD $50M+ small biotech savings from not having to reinvent the wheel Best-in-world capabilities create value.#9CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 9 STRATEGY #2 Build a large, diverse portfolio of stakes in future antibody therapies. PARTNER-INITIATED PROGRAMS Discovery Programs Co-Development Programs X TECHNOLOGY-DEVELOPMENT Pre-Partnered Programs#10CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 10 PARTNER-INITIATED PROGRAMS Discovery Programs TARGET Partner-initiated DEAL TERMS Upfronts and research fees Clinical milestones Single-digit royalties on net sales ● ● High volume deals with highly diversified positions and high ROI.#11CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 11 PARTNER-INITIATED PROGRAMS Co-Development Programs TARGET Partner-initiated DEAL TERMS Upfronts, clinical milestones, and royalty position PLUS option to co-invest in program development to maintain up to a 50% ownership position ● Low volume deals with optionality for concentrated positions.#12CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 12 TECHNOLOGY-DEVELOPMENT Pre-Partnered Programs Untapped market opportunity in an area with a high technical barrier to entry and a rich target space that includes many targets. T-Cell Engagers Platform GPCRs & Ion Channels Platform Pandemic Response Platform High-value, well-validated targets that have been intractable using fragmented approaches and traditional technology. Tech-intensive challenge requiring complex integration to deliver antibody therapies quickly and bring new treatments to address emerging variants. Technology development efforts with potential to generate first-in-class wholly-owned assets.#13CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 13 PRE-PARTNERED PROGRAMS: PANDEMIC RESPONSE FIRST PRE-PARTNERED PROGRAM IN COVID-19 RESULTED IN TREATMENTS FOR ~2.5M PATIENTS Together with our partner, Lilly, AbCellera co-developed two antibody treatments authorized by the US FDA to treat COVID-19. bamlanivimab Nov 2020 - US FDA Authorization bebtelovimab Feb 2022- US FDA Authorization new candidate Today - 3rd therapeutic antibody for COVID-19 in preclinical development#14CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 14 PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, AND DEAL TYPE. 84 7 partner-initiated partner-initiated discovery programs co-development programs 38 partners 7 molecules in the clinic 15 pre-partnered program targets initiated (GPCR, ion channels and TCE) 2 authorized antibody therapies REGENERON gsk NOVARTIS GILEAD Ablynx A SANOFI COMPANY EMPIRICO Autolus TACHYON Lilly EVEREST MEDICINES SANOFI igences Rallybio angios Lyell teva moderna TM REMAKING MEDICINE Pfizer KODIAK DENALI X Invetx MERCK BILL & MELINDA GATES foundation#15CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 15 10 YEARS BUILDING THE ENGINE. capitalization ~$800M in equity raised since 2012 $150M+ in government contracts and financing 30% + held by employees & directors investments ~500 employees across 4 countries and 3 continents 640K+ sq.ft. of facilities lab, office, & manufacturing spaces by 2024 $500M+ platform investments financials ~$860M in cash, cash equivalents & marketable securities $450M in accumulated earnings since 2012 KIMTECH#16CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 16 2 TECHNOLOGY 3 & COMPANY BUILDING H|M PARTNERING PARTNERED PROGRAMS Deal quality, not volume Deeper partnerships that get partners to the clinic Execute on and expand existing partnerships PRE-PARTNERED ● ● ● PROGRAMS GPCRs and ion channels T-cell engagers Pandemic response (COVID-19) PEOPLE & PLATFORM Team development Data science ● ● ● Translational science Manufacturing AbCellera's capital allocation#17CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 17 IT'S BECAUSE IT'S HARD THAT IT'S VALUABLE & IT'S DEFENSIBLE. AbCellera's competitive moat CAPITAL TECHNOLOGY DATA SCIENCE THE ENGINE EXPERTS SCALE INFRASTRUCTURE INTEGRATION TIME#18CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 18 This is what's needed to solve the problem. FROM TARGET TO DRUG#1919 COPYRIGHT © ABCELLERA CORPORATE OVERVIEW THANK YOU